Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BLM | P54132 | 2/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.62 |
| ▸ | HPGD | P15428 | 2/20 | 0.62 |
| ▸ | POLB | P06746 | 2/20 | 0.62 |
| ▸ | APEX1 | P27695 | 2/20 | 0.62 |
| ▸ | RECQL | P46063 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | USP2 | O75604 | 1/20 | 0.62 |
| ▸ | EGFR | P00533 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | FYN | P06241 | 1/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | GAA | P10253 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.62 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.62 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14547348 | 1.00 | BLM (0.73) | BLMALDH1A1TDP1HPGDPOLB | |
| Hydrochloric Acid SCHEMBL11335295 | 0.85 | BLM (0.73) | BLMALDH1A1TDP1HPGDPOLB | |
| Hydrochloric Acid SCHEMBL11335298 | 0.85 | BLM (0.73) | BLMALDH1A1TDP1HPGDPOLB | |
| Metyrosine SCHEMBL50398 | 0.85 | BLM (1.00) | BLMALDH1A1TDP1HPGDPOLB | |
| SCHEMBL6717498 | 0.85 | BLM (0.73) | BLMALDH1A1TDP1HPGDPOLB | |
| SCHEMBL12659218 | 0.85 | BLM (0.53) | BLMALDH1A1TDP1HPGDPOLB | |
| SCHEMBL6717499 | 0.85 | BLM (0.73) | BLMALDH1A1TDP1HPGDPOLB | |
| Racemetyrosine SCHEMBL61871 | 0.85 | BLM (1.00) | BLMALDH1A1TDP1HPGDPOLB | |
| Metyrosine SCHEMBL162280 | 0.85 | BLM (1.00) | BLMALDH1A1TDP1HPGDPOLB | |
| Metyrosine SCHEMBL5053839 | 0.85 | BLM (1.00) | BLMALDH1A1TDP1HPGDPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9630989-B2 | Dipeptide analogs for treating conditions associated with amyloid fibril formation | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2017-04-25 | — | — | US | disclosed |
| US-20150322110-A1 | DIPEPTIDE ANALOGS FOR TREATING CONDITIONS ASSOCIATED WITH AMYLOID FIBRIL FORMATION | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2015-11-12 | — | — | US | disclosed |
| US-9096645-B2 | Dipeptide analogs for treating conditions associated with amyloid fibril formation | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2015-08-04 | — | — | US | disclosed |
| US-20130225512-A1 | DIPEPTIDE ANALOGS FOR TREATING CONDITIONS ASSOCIATED WITH AMYLOID FIBRIL FORMATION | MERZ PHARMA GMBH & CO. KGAA (DE) | 2013-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150322110-A1 | DIPEPTIDE ANALOGS FOR TREATING CONDITIONS ASSOCIATED WITH AMYLOID FIBRIL FORMATION | IAPP, APP, APBA1 | BLM 868/4885ALDH1A1 3599/4885TDP1 560/4885 |
| US-20130225512-A1 | DIPEPTIDE ANALOGS FOR TREATING CONDITIONS ASSOCIATED WITH AMYLOID FIBRIL FORMATION | IAPP, APP, APBA1 | BLM 880/4885ALDH1A1 3602/4885TDP1 567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.